Sermorelin and cancer risk: an honest look

The chain from sermorelin to IGF-1

Sermorelin is a shortened version of growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone in its natural pulses, and growth hormone in turn signals the liver to make IGF-1. MedlinePlus describes IGF-1 as the hormone that carries out many of growth hormone's effects on tissue growth.

Growth signals are useful for healing and maintaining tissue. The worry is that the same signals could, in theory, help existing abnormal cells grow faster. That concern applies to anything that meaningfully raises IGF-1.

What population studies show

The largest data come from the UK Biobank, which measured IGF-1 in hundreds of thousands of adults and followed them for years. An analysis in Cancer Research covering 30 cancer types found that higher circulating IGF-1 was associated with higher risk of colorectal, breast and prostate cancer, with limited evidence for less common cancers. A separate analysis in nearly 200,000 men examined IGF-1 and testosterone together in relation to prostate cancer.

These associations are generally modest, and they describe people's natural IGF-1 levels, not levels raised by medicine. They do not prove that raising IGF-1 causes cancer, but they are the reason careful clinicians avoid pushing IGF-1 high.

What the evidence does not show

• No randomized trial has tested whether sermorelin changes cancer risk.
• Studies of sermorelin in adults have been small and short, too small to detect uncommon outcomes like cancer.
• There are no published controlled trials of a sermorelin dissolving tablet, and absorption by mouth is not established.
• Absence of evidence of harm here reflects missing studies, not proof of safety.

Is it different from taking growth hormone?

In principle, sermorelin works through your own pituitary, which keeps the natural pulse pattern and the body's feedback controls. That may limit how high growth hormone and IGF-1 go compared with injecting growth hormone directly. This is a reasonable theory, but it has not been tested in head-to-head studies for cancer outcomes, so it should not be read as a safety guarantee.

Putting the risk in perspective

For most midlife adults, the biggest drivers of cancer risk are well known: age, smoking, alcohol, excess weight, inactivity, family history and missed screening. A theoretical IGF-1 effect from a modest dose of sermorelin is likely to be small next to those, but small is not the same as zero, and the benefits of sermorelin in healthy adults are themselves uncertain.

That balance is the core of the decision. When the potential benefit is modest and unproven, it makes sense to set a low bar for stopping and a high bar for starting in anyone with extra risk factors.

Who should not take sermorelin

• Anyone with active cancer or under evaluation for a possible cancer.
• People with a past cancer, especially a hormone-sensitive one, unless their oncologist agrees after discussion; often the answer will be no.
• People with a pituitary tumor or untreated pituitary disease.
• Anyone who is pregnant or breastfeeding, and people under 18.
• People with a strong family history of colorectal, breast or prostate cancer who are not up to date with screening.

Safeguards your clinician uses

Before prescribing, your HealifyMD clinician reviews your personal and family cancer history and checks that age-appropriate screening, such as colonoscopy, mammography and a PSA discussion, is current. IGF-1 is measured at baseline and again during treatment, with the aim of staying within a range reasonable for your age rather than reaching the top of it.

If IGF-1 rises higher than intended, or if new symptoms appear, the dose is reduced or treatment stopped. Any new lump, unexplained weight loss, bleeding or persistent change in bowel or urinary habits should be reported promptly and evaluated in person.

Regulatory status and cost

Sermorelin injection was previously FDA-approved as Geref for growth hormone deficiency in children and for testing pituitary function. It was discontinued in 2008, and in 2013 the FDA determined it was not withdrawn for safety or effectiveness reasons. Sermorelin is now available only through compounding pharmacies.

Sermorelin ODT through HealifyMD is compounded by a licensed U.S. pharmacy. It is not FDA-approved, has not been reviewed by the FDA for safety, effectiveness or quality and is not equivalent to the former branded product. It is from $199/month, confirmed at the eligibility review, with labs priced separately. We do not market it as anti-aging.